Core Insights - Norska's stock price decreased by 2.00% on November 12, trading at 61.24 CNY per share with a market capitalization of 5.915 billion CNY [1] - The company has seen a year-to-date stock price increase of 22.89%, but a recent decline of 7.13% over the last five trading days [1] Financial Performance - For the period from January to September 2025, Norska achieved a revenue of 607 million CNY, representing a year-on-year growth of 8.09% [2] - The net profit attributable to shareholders for the same period was 95.5668 million CNY, reflecting a year-on-year increase of 13.21% [2] Business Overview - Norska, established on August 22, 2008, specializes in clinical trial operation services, clinical trial site management services, biological sample testing services, data management and statistical analysis services, clinical trial consulting services, and clinical pharmacology services [2] - The revenue composition of Norska's main business includes: 39.25% from clinical trial operation services, 34.10% from clinical trial site management services, 13.30% from data management and statistical analysis services, 8.45% from biological sample testing services, 3.74% from clinical pharmacology services, and 1.16% from clinical trial consulting services [2] Shareholder Information - As of September 30, 2025, Norska had 8,734 shareholders, a decrease of 16.18% from the previous period, with an average of 6,545 circulating shares per shareholder, an increase of 19.30% [2] - The company has distributed a total of 49.4969 million CNY in dividends since its A-share listing [3]

Core Points - The stock price of Norska dropped by 2.14% on November 7, trading at 63.21 CNY per share with a market capitalization of 6.105 billion CNY [1] - Norska's stock has increased by 26.85% year-to-date, but has seen a decline of 7.84% over the last five trading days [1] - The company has been listed on the stock market since August 2, 2022, and specializes in clinical trial operation services and related fields [1] Financial Performance - For the period from January to September 2025, Norska reported a revenue of 607 million CNY, reflecting a year-on-year growth of 8.09% [2] - The net profit attributable to shareholders for the same period was 95.5668 million CNY, marking a year-on-year increase of 13.21% [2] - Cumulative cash dividends since the A-share listing amount to 49.4969 million CNY [2] Shareholder Information - As of September 30, 2025, the number of shareholders decreased by 16.18% to 8,734 [2] - The average number of circulating shares per shareholder increased by 19.30% to 6,545 shares [2] - Notable changes in institutional holdings include the entry of Nuoan Pioneer Mixed A as the sixth largest shareholder with 1.6796 million shares [2]

Core Insights - The company reported a revenue of 607 million yuan for the first three quarters of 2025, representing an 8.09% year-on-year increase [1] - The net profit attributable to shareholders was 95.57 million yuan, up 13.21% year-on-year, while the net profit excluding non-recurring items was 81.33 million yuan, reflecting a 22.47% increase [1] - The basic earnings per share stood at 1.00 yuan [1] Financial Performance - The gross profit margin for the first three quarters of 2025 was 35.61%, a decrease of 3.58 percentage points year-on-year, while the net profit margin was 15.94%, an increase of 0.66 percentage points compared to the same period last year [2] - In Q3 2025, the gross profit margin was 32.74%, down 4.61 percentage points year-on-year and 5.26 percentage points quarter-on-quarter; the net profit margin was 15.50%, up 1.14 percentage points year-on-year but down 1.49 percentage points from the previous quarter [2] - Total operating expenses for Q3 2025 were 114 million yuan, a decrease of 20.86 million yuan year-on-year, with an expense ratio of 18.82%, down 5.23 percentage points year-on-year [2] Shareholder Information - As of the end of Q3 2025, the total number of shareholders was 8,734, a decrease of 1,686 or 16.18% from the end of the first half of the year; the average market value per shareholder increased by 37.25% from 443,100 yuan to 608,200 yuan [2] Business Overview - The company, established on August 22, 2008, and listed on August 2, 2022, is located in Haidian District, Beijing, and specializes in clinical trial operation services, clinical trial site management services, biological sample testing services, data management and statistical analysis services, clinical trial consulting services, and clinical pharmacology services [3] - The revenue composition of the main business includes: 39.25% from clinical trial operation services, 34.10% from clinical trial site management services, 13.30% from data management and statistical analysis services, 8.45% from biological sample testing services, 3.74% from clinical pharmacology services, and 1.16% from clinical trial consulting services [3] - The company belongs to the pharmaceutical and biotechnology industry, specifically in medical services and medical research outsourcing [3]

Core Insights - On October 10, Norscare experienced a decline of 3.08% with a trading volume of 97.24 million yuan [1] - The company reported a financing buy-in amount of 15.63 million yuan and a net financing buy of 10.66 million yuan on the same day [1] Financing Overview - As of October 10, the total financing and securities lending balance for Norscare was 10.4 million yuan, accounting for 3.45% of its market capitalization [1] - The current financing balance exceeds the 80th percentile level over the past year, indicating a high level of financing activity [1] Securities Lending Overview - On October 10, there were no shares repaid or sold in the securities lending market, resulting in a sell amount of 0 yuan [1] - The securities lending balance also stands at 0 yuan, which is above the 80th percentile level over the past year, indicating a high level of inactivity in this area [1] Company Profile - Norscare (Beijing) Medical Technology Co., Ltd. was established on August 22, 2008, and went public on August 2, 2022 [2] - The company specializes in clinical trial operation services, clinical trial site management services, biological sample testing services, data management and statistical analysis services, clinical trial consulting services, and clinical pharmacology services [2] - The revenue composition includes: clinical trial operation services (39.25%), clinical trial site management services (34.10%), data management and statistical analysis services (13.30%), biological sample testing services (8.45%), clinical pharmacology services (3.74%), and clinical trial consulting services (1.16%) [2] Financial Performance - For the period from January to June 2025, Norscare achieved a revenue of 380 million yuan, reflecting a year-on-year growth of 0.18% [2] - The net profit attributable to the parent company was 61.12 million yuan, representing a year-on-year increase of 4.45% [2] Shareholder Information - As of June 30, 2025, Norscare had 10,400 shareholders, an increase of 2.06% from the previous period [2] - The average number of circulating shares per shareholder was 5,486, a decrease of 1.97% from the previous period [2] - The company has distributed a total of 49.50 million yuan in dividends since its A-share listing [3]

Core Viewpoint - Norska's stock price has shown a positive trend with an 8.48% increase year-to-date, reflecting investor confidence in the company's growth potential in the clinical trial services sector [2]. Company Overview - Norska (Beijing) Pharmaceutical Technology Co., Ltd. was established on August 22, 2008, and went public on August 2, 2022. The company is located in Haidian District, Beijing [2]. - The company's main business includes clinical trial operation services, clinical trial site management services, biological sample testing services, data management and statistical analysis services, clinical trial consulting services, and clinical pharmacology services [2]. - Revenue composition: Clinical trial operation services (39.25%), clinical trial site management services (34.10%), data management and statistical analysis services (13.30%), biological sample testing services (8.45%), clinical pharmacology services (3.74%), and clinical trial consulting services (1.16%) [2]. Financial Performance - For the first half of 2025, Norska achieved operating revenue of 380 million yuan, a year-on-year increase of 0.18%, and a net profit attributable to shareholders of 61.12 million yuan, up 4.45% year-on-year [2]. - Cumulative cash dividends since the A-share listing amount to 49.50 million yuan [3]. Shareholder Information - As of June 30, 2025, the number of shareholders increased to 10,400, with an average of 5,486 circulating shares per person, a decrease of 1.97% from the previous period [2]. - New significant shareholders include Hong Kong Central Clearing Limited and two funds from Zhonggeng, indicating growing institutional interest [3].

Group 1 - The core point of the news is that Norscare's stock has experienced a decline of 5.08% on September 23, with a total market value of 5.072 billion yuan and a cumulative drop of 4.6% over the past four days [1] - Norscare (Beijing) Pharmaceutical Technology Co., Ltd. was established on August 22, 2008, and went public on August 2, 2022. The company specializes in clinical trial operation services, clinical trial site management services, biological sample testing services, data management and statistical analysis services, clinical trial consulting services, and clinical pharmacology services [1] - The revenue composition of Norscare's main business includes: clinical trial operation services (39.25%), clinical trial site management services (34.10%), data management and statistical analysis services (13.30%), biological sample testing services (8.45%), clinical pharmacology services (3.74%), and clinical trial consulting services (1.16%) [1] Group 2 - From the perspective of fund holdings, one fund under Dongcai has a significant position in Norscare, with Dongcai Vision Growth Mixed Initiation A (018088) holding 12,400 shares, accounting for 4.85% of the fund's net value, ranking as the fifth-largest holding [2] - The fund has experienced a floating loss of approximately 34,800 yuan today, with a cumulative floating loss of 33,100 yuan during the four-day decline [2] - Dongcai Vision Growth Mixed Initiation A (018088) was established on April 11, 2023, with a latest scale of 9.6956 million yuan, and has achieved a year-to-date return of 46.64% [2]

Group 1 - Norsg's stock price increased by 5.35% on September 10, reaching 61.80 CNY per share, with a trading volume of 263 million CNY and a turnover rate of 7.73%, resulting in a total market capitalization of 5.969 billion CNY [1] - The stock has risen for eight consecutive days, with a cumulative increase of 13.95% during this period [1] - Norsg (Beijing) Pharmaceutical Technology Co., Ltd. specializes in clinical trial operation services, clinical trial site management services, biological sample testing services, data management and statistical analysis services, clinical trial consulting services, and clinical pharmacology services [1] Group 2 - The East Finance Growth Mixed Fund A (018088) holds 12,400 shares of Norsg, accounting for 4.85% of the fund's net value, making it the fifth-largest holding [2] - The fund has generated a floating profit of approximately 38,900 CNY today and 89,000 CNY during the eight-day rising period [2] - The fund was established on April 11, 2023, with a latest scale of 9.6956 million CNY and has achieved a year-to-date return of 47.97% [2]

Group 1 - The core point of the article highlights the recent performance of Norscare, which saw a stock price increase of 5.28% to 58.00 CNY per share, with a total market capitalization of 5.602 billion CNY and a cumulative increase of 7.01% over four consecutive days [1] - Norscare specializes in clinical trial operation services, clinical trial site management services, biological sample testing services, data management and statistical analysis services, clinical trial consulting services, and clinical pharmacology services [1] - The revenue composition of Norscare's main business includes: clinical trial operation services (43.01%), clinical trial site management services (27.52%), data management and statistical analysis services (13.53%), biological sample testing services (8.54%), clinical pharmacology services (4.33%), and clinical trial consulting services (3.08%) [1] Group 2 - Data indicates that a fund under Tibet Dongcai has a significant holding in Norscare, with the Dongcai Vision Growth Mixed Fund A (018088) holding 12,400 shares, representing 4.85% of the fund's net value, ranking as the fifth largest holding [2] - The Dongcai Vision Growth Mixed Fund A has achieved a year-to-date return of 47.41% and a one-year return of 84.81%, ranking 760 out of 8180 and 595 out of 7978 respectively [2] - The fund manager, Sun Chenyang, has a tenure of 2 years and 148 days, with the best fund return during this period being 39.2% and the worst being -28.98% [2]

Core Insights - On August 29, Norscare's stock rose by 2.93% with a trading volume of 166 million yuan [1] - The company reported a financing buy-in of 15.92 million yuan and a financing repayment of 17.69 million yuan, resulting in a net financing outflow of 1.77 million yuan [1] - As of August 29, the total financing and securities lending balance for Norscare was 84.92 million yuan, which is 2.80% of its market capitalization, indicating a high level of financing balance compared to the past year [1] Company Overview - Norscare (Beijing) Pharmaceutical Technology Co., Ltd. was established on August 22, 2008, and went public on August 2, 2022 [2] - The company specializes in clinical trial operation services, clinical trial site management services, biological sample testing services, data management and statistical analysis services, clinical trial consulting services, and clinical pharmacology services [2] - The revenue composition includes: clinical trial operation services (43.01%), clinical trial site management services (27.52%), data management and statistical analysis services (13.53%), biological sample testing services (8.54%), clinical pharmacology services (4.33%), and clinical trial consulting services (3.08%) [2] Financial Performance - For the first half of 2025, Norscare achieved a revenue of 380 million yuan, representing a year-on-year growth of 0.18% [2] - The net profit attributable to the parent company was 61.12 million yuan, reflecting a year-on-year increase of 4.45% [2] - Cumulative cash dividends since the A-share listing amount to 49.50 million yuan [3] Shareholder Structure - As of June 30, 2025, the number of shareholders for Norscare was 10,400, an increase of 2.06% from the previous period [2] - The average number of circulating shares per shareholder was 5,486, a decrease of 1.97% from the previous period [2] - New institutional shareholders include Hong Kong Central Clearing Limited and two funds from Zhonggeng, which entered the top ten circulating shareholders [3]

Core Viewpoint - The company Norse Group (Beijing) Pharmaceutical Technology Co., Ltd. has shown stable financial performance with slight growth in revenue and net profit, while also experiencing significant trading activity in its stock. Group 1: Financial Performance - For the period from January to June 2025, Norse Group achieved operating revenue of 380 million yuan, representing a year-on-year growth of 0.18% [2] - The net profit attributable to the parent company was 61.12 million yuan, reflecting a year-on-year increase of 4.45% [2] - Cumulative cash dividends since the company's A-share listing amounted to 49.50 million yuan [3] Group 2: Business Operations - The company's main business segments include clinical trial operation services (43.01%), clinical trial site management services (27.52%), data management and statistical analysis services (13.53%), biological sample testing services (8.54%), clinical pharmacology services (4.33%), and clinical trial consulting services (3.08%) [2] - As of June 30, 2025, the number of shareholders increased to 10,400, up by 2.06% from the previous period, while the average circulating shares per person decreased by 1.97% to 5,486 shares [2] Group 3: Stock Trading Activity - On August 28, Norse Group's stock price fell by 0.39%, with a trading volume of 149 million yuan [1] - The financing buy-in amount for Norse Group on the same day was 19.42 million yuan, with a net buy of 5.95 million yuan after 13.47 million yuan in financing repayments [1] - The total financing and securities lending balance reached 86.69 million yuan, accounting for 2.94% of the circulating market value, indicating a high level compared to the past year [1]